Clinical Trials to Combat Covid-19 (CTCC): Case Based Approach (CBA) of a NSE Listed Indian Pharmaceutical Company

M. Nandy
{"title":"Clinical Trials to Combat Covid-19 (CTCC): Case Based Approach (CBA) of a NSE Listed Indian Pharmaceutical Company","authors":"M. Nandy","doi":"10.21567/10.21567/ADHYAYAN.V10I1.1","DOIUrl":null,"url":null,"abstract":"Purpose\n Clinical Trials to Combat Covid-19 (CTCC) case study had been developed on a National Stock Exchange (NSE) listed Indian pharmaceutical company. The main intention to develop this case study was to understand how the research and development (RandD) and innovative activities were being performed during crisis period to combat Covid-19.\n Design / Methodology / Approach\n The study period to develop this case was May 2020 to June 2020. Published official reports and press releases were considered for the study. Basic arithmetic and statistics had been incorporated for data driven analysis and interpretation. Microsoft Excel (most updated version) had been used for econometrics analysis and visual representation. Content Analysis Technique had been adopted to draw appropriate information, insights, and inferences. Trendline Analysis of the share price had been performed with the help of Y = mx + c regression equation with a univariate variable.\n Findings\n Clinical trial endeavor being rendered by the sample company subsequently made enable to obtain approval from the regulatory body (DGCI), which impacted share price increase by 9% and this increment was supported by R Square value 1 (100%) followed by the increment value of 29.64x (where x was independent variable). There was a linear upward trend observed. It had been found that the company became 1st in India to initiate clinical trial to combat Covid-19 on two specific drugs Favipiravir and Umifenovir. The company’s clinical trial study dubbed ‘FAITH trial’ would involve 158 hospitalized patients in India who had moderate symptoms of coronavirus infection. Leadership during the crisis period had also been observed with the dedicated activities of the RandD team of the company. At last, it had been found that the company is extremely optimistic and confident with their dedicated and painstaking efforts to provide the answer of the unknown through their innovative activities and serve the nation as well as the entire world with innovative healthcare solution to combat Covid-19 and finally the company would eagerly wait for those days to come.","PeriodicalId":228193,"journal":{"name":"Adhyayan: A Journal of Management Sciences","volume":"167 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Adhyayan: A Journal of Management Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21567/10.21567/ADHYAYAN.V10I1.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose Clinical Trials to Combat Covid-19 (CTCC) case study had been developed on a National Stock Exchange (NSE) listed Indian pharmaceutical company. The main intention to develop this case study was to understand how the research and development (RandD) and innovative activities were being performed during crisis period to combat Covid-19. Design / Methodology / Approach The study period to develop this case was May 2020 to June 2020. Published official reports and press releases were considered for the study. Basic arithmetic and statistics had been incorporated for data driven analysis and interpretation. Microsoft Excel (most updated version) had been used for econometrics analysis and visual representation. Content Analysis Technique had been adopted to draw appropriate information, insights, and inferences. Trendline Analysis of the share price had been performed with the help of Y = mx + c regression equation with a univariate variable. Findings Clinical trial endeavor being rendered by the sample company subsequently made enable to obtain approval from the regulatory body (DGCI), which impacted share price increase by 9% and this increment was supported by R Square value 1 (100%) followed by the increment value of 29.64x (where x was independent variable). There was a linear upward trend observed. It had been found that the company became 1st in India to initiate clinical trial to combat Covid-19 on two specific drugs Favipiravir and Umifenovir. The company’s clinical trial study dubbed ‘FAITH trial’ would involve 158 hospitalized patients in India who had moderate symptoms of coronavirus infection. Leadership during the crisis period had also been observed with the dedicated activities of the RandD team of the company. At last, it had been found that the company is extremely optimistic and confident with their dedicated and painstaking efforts to provide the answer of the unknown through their innovative activities and serve the nation as well as the entire world with innovative healthcare solution to combat Covid-19 and finally the company would eagerly wait for those days to come.
抗Covid-19临床试验(CTCC):一家印度国家证券交易所上市的印度制药公司的基于病例的方法(CBA
目的:在国家证券交易所(NSE)上市的印度制药公司开展了抗Covid-19临床试验(CTCC)案例研究。开展这一案例研究的主要目的是了解在危机期间如何开展研发(RandD)和创新活动以抗击Covid-19。设计/方法/方法本案例的研究期为2020年5月至2020年6月。这项研究考虑了已出版的官方报告和新闻稿。基本的算术和统计已被纳入数据驱动的分析和解释。使用Microsoft Excel(最新版本)进行计量经济学分析和可视化表示。内容分析技术已被采用,以得出适当的信息,见解和推论。利用单变量Y = mx + c回归方程对股价进行趋势线分析。样本公司的临床试验努力随后获得了监管机构(DGCI)的批准,这对股价上涨产生了9%的影响,这一增量由R平方值1(100%)支持,然后是29.64x的增量值(其中x为自变量)。观察到线性上升的趋势。据悉,该公司在印度率先启动了两种特定药物Favipiravir和Umifenovir的临床试验,以对抗新冠病毒。该公司的临床试验研究被称为“FAITH试验”,将涉及158名印度住院的冠状病毒感染中度症状患者。危机期间的领导能力也通过公司研发团队的专门活动得到了观察。最后,我们发现公司非常乐观和自信,他们将通过创新活动提供未知的答案,并通过创新的医疗解决方案为国家和全世界服务,以对抗新冠肺炎,最终公司将热切地等待这一天的到来。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信